Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Tancini

Showing results (161-170 of 218) with videos related to

Pageof 22
Sort By:
Tumori|July 1, 1995
Clinical efficacy of cancer subcutaneous immunotherapy with interleukin-2 in relation to the pretreatment levels of tumor growth factor insulin-like growth factor-1P Lissoni, S Barni, A Ardizzoia, et al.
Anticancer Research|June 25, 2003
Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinationsG Cerea, M Vaghi, A Ardizzoia, et al.
Oncology|May 1, 1995
A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folatesS Barni, P Lissoni, M Cazzaniga, et al.
Tumori|June 30, 1991
Neuroendocrine effects of subcutaneous interleukin-2 injection in cancer patientsP Lissoni, S Barni, F Rovelli, et al.
Oncology|January 1, 1990
Pineal gland and tumor cell kinetics: serum levels of melatonin in relation to Ki-67 labeling rate in breast cancerP Lissoni, S Crispino, S Barni, et al.
Recenti Progressi in Medicina|June 1, 1995
Prevention of interleukin-2-induced thrombocytopenia during the immunotherapy of cancer by a concomitant administration of the pineal hormone melatoninE R Bregani, P Lissoni, F Rossini, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Postoperative hyperprolactinaemia and early recurrence rate in breast cancerP Lissoni, A L Sormani, G Tancini, et al.
Journal of Biological Regulators and Homeostatic Agents|October 1, 1991
Modulation of interleukin-2-induced macrophage activation in cancer patients by the pineal hormone melatoninP Lissoni, E Tisi, F Brivio, et al.
NCI Monographs : a Publication of the National Cancer Institute|January 1, 1986
Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancerG Bonadonna, P Valagussa, G Tancini, et al.
British Journal of Cancer|November 1, 1991
Decrease in cholesterol levels during the immunotherapy of cancer with interleukin-2P Lissoni, F Brivio, S Pittalis, et al.
Pageof 22

Showing results (161-170 of 218) with videos related to

Sort By:
Pageof 22
Tumori|July 1, 1995
Clinical efficacy of cancer subcutaneous immunotherapy with interleukin-2 in relation to the pretreatment levels of tumor growth factor insulin-like growth factor-1P Lissoni, S Barni, A Ardizzoia, et al.
Anticancer Research|June 25, 2003
Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinationsG Cerea, M Vaghi, A Ardizzoia, et al.
Oncology|May 1, 1995
A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folatesS Barni, P Lissoni, M Cazzaniga, et al.
Tumori|June 30, 1991
Neuroendocrine effects of subcutaneous interleukin-2 injection in cancer patientsP Lissoni, S Barni, F Rovelli, et al.
Oncology|January 1, 1990
Pineal gland and tumor cell kinetics: serum levels of melatonin in relation to Ki-67 labeling rate in breast cancerP Lissoni, S Crispino, S Barni, et al.
Recenti Progressi in Medicina|June 1, 1995
Prevention of interleukin-2-induced thrombocytopenia during the immunotherapy of cancer by a concomitant administration of the pineal hormone melatoninE R Bregani, P Lissoni, F Rossini, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Postoperative hyperprolactinaemia and early recurrence rate in breast cancerP Lissoni, A L Sormani, G Tancini, et al.
Journal of Biological Regulators and Homeostatic Agents|October 1, 1991
Modulation of interleukin-2-induced macrophage activation in cancer patients by the pineal hormone melatoninP Lissoni, E Tisi, F Brivio, et al.
NCI Monographs : a Publication of the National Cancer Institute|January 1, 1986
Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancerG Bonadonna, P Valagussa, G Tancini, et al.
British Journal of Cancer|November 1, 1991
Decrease in cholesterol levels during the immunotherapy of cancer with interleukin-2P Lissoni, F Brivio, S Pittalis, et al.
Pageof 22